Phenotypes Associated with This Genotype

Genotype
MGI:4361450

• Allelic Composition: Peli1^tm1Tigm/Peli1^tm1Tigm
• Genetic Background: involves: 129/Sv * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

decreased susceptibility to xenobiotic induced morbidity/mortality ( J:152781 )

• unlike similarly treated wild-type mice, treatment with LPS or pIpC does not induce lethality

immune system

increased B cell apoptosis ( J:152781 )

• B cells exhibit severe attenuation of the prosurvival effects of LPS, pIpC, and CpG

decreased B cell proliferation ( J:152781 )

• following treatment with LPS or pIpC, B cell proliferation is decreased compared to in similarly treated wild-type mice

• CpG- and CSK4-induced B cell proliferation are partially inhibited compared to in similarly treated wild-type mice

• however, B cell proliferation induced by R-837, MALP-2, IgM, CD40, or PGN is normal

decreased circulating interferon-beta level ( J:152781 )

• compared with similarly treated wild-type mice following treatment with LPS or pIpC

decreased circulating interleukin-12b level ( J:152781 )

• in LPS, pIpC, or CpG treated bone marrow-derived dendritic cells

decreased circulating interleukin-6 level ( J:152781 )

• compared with similarly treated wild-type mice following treatment with LPS, pIpC, or IL1beta

decreased circulating tumor necrosis factor level ( J:152781 )

• compared with similarly treated wild-type mice following treatment with LPS or pIpC

decreased interleukin-12 secretion ( J:152781 )

• in LPS, pIpC, or CpG treated bone marrow-derived dendritic cells

decreased susceptibility to endotoxin shock ( J:152781 )

• unlike similarly treated wild-type mice, treatment with LPS or pIpC leads to attenuated proinflammatory cytokine (TNF, IL6, IL12b, and IFN-beta) production, leads to decreased proliferation of B cells, and fails to induce lethality

• CpG- and CSK4-induced B cell proliferation are partially inhibited compared to in similarly treated wild-type mice

• however, B cell proliferation induced by R-837, MALP-2, IgM, CD40, or PGN is normal

• B cells exhibit severe attenuation of the prosurvival effects of LPS, pIpC, and CpG

homeostasis/metabolism

decreased circulating interferon-beta level ( J:152781 )

• compared with similarly treated wild-type mice following treatment with LPS or pIpC

decreased circulating interleukin-12b level ( J:152781 )

• in LPS, pIpC, or CpG treated bone marrow-derived dendritic cells

decreased circulating interleukin-6 level ( J:152781 )

• compared with similarly treated wild-type mice following treatment with LPS, pIpC, or IL1beta

decreased circulating tumor necrosis factor level ( J:152781 )

• compared with similarly treated wild-type mice following treatment with LPS or pIpC

decreased susceptibility to xenobiotic induced morbidity/mortality ( J:152781 )

• unlike similarly treated wild-type mice, treatment with LPS or pIpC does not induce lethality

hematopoietic system

increased B cell apoptosis ( J:152781 )

• B cells exhibit severe attenuation of the prosurvival effects of LPS, pIpC, and CpG

decreased B cell proliferation ( J:152781 )

• following treatment with LPS or pIpC, B cell proliferation is decreased compared to in similarly treated wild-type mice

• CpG- and CSK4-induced B cell proliferation are partially inhibited compared to in similarly treated wild-type mice

• however, B cell proliferation induced by R-837, MALP-2, IgM, CD40, or PGN is normal

cellular

increased B cell apoptosis ( J:152781 )

• B cells exhibit severe attenuation of the prosurvival effects of LPS, pIpC, and CpG

decreased B cell proliferation ( J:152781 )

• following treatment with LPS or pIpC, B cell proliferation is decreased compared to in similarly treated wild-type mice

• CpG- and CSK4-induced B cell proliferation are partially inhibited compared to in similarly treated wild-type mice

• however, B cell proliferation induced by R-837, MALP-2, IgM, CD40, or PGN is normal